Why "Formulary Exception" Undersells the Real Problem
Search "formulary exception for Dupixent" and you'd reasonably expect the issue to be that Dupixent isn't on your plan's drug list. For most patients, that's not actually what's happening. Dupixent is a specialty-tier drug covered on the overwhelming majority of commercial and Medicare Part D formularies — its own manufacturer cites roughly 99% Part D coverage, a figure covered in more depth in our Dupixent savings card guide. A true non-formulary exception, where the drug simply isn't listed at all, is the exception rather than the rule here.
What's actually driving most Dupixent coverage denials is narrower and, honestly, more interesting: Dupixent treats nine separate, medically unrelated conditions, and payers evaluate coverage for each one separately, with its own clinical bar to clear. Understanding that structure — and where it breaks down — matters more than understanding the generic mechanics of a formulary exception request.
Nine Indications, Nine Different Checklists
Because Dupixent's approved uses span dermatology, pulmonology, gastroenterology, and immunology, no single "prerequisite therapy" rule applies across the board. A payer's clinical policy typically treats each indication as its own section, with its own required prior treatments and its own clinical documentation.
| Indication | Typical Prerequisite Documentation |
|---|---|
| Atopic dermatitis (eczema) | Trial of medium-to-high potency topical corticosteroids or topical calcineurin inhibitors; often a systemic therapy trial for adults |
| Asthma | Documented uncontrolled symptoms despite a high-dose inhaled corticosteroid plus at least one additional controller for a defined period, often with eosinophil count or exacerbation history |
| Chronic rhinosinusitis with nasal polyps (CRSwNP) | Trial of intranasal or topical corticosteroids, sometimes with a history of sinus surgery |
| Eosinophilic esophagitis | Diagnostic confirmation via biopsy and eosinophil count, with prior therapy documentation varying by plan |
| COPD with an eosinophilic phenotype | Documented exacerbation history despite maintenance triple therapy (a long-acting muscarinic antagonist, a long-acting beta agonist, and an inhaled corticosteroid), plus a minimum blood eosinophil count |
| Chronic spontaneous urticaria | Documented symptoms despite H1 antihistamine treatment |
| Bullous pemphigoid | Clinical diagnosis plus trial of high-potency topical or oral corticosteroids |
| Allergic fungal rhinosinusitis | Diagnostic confirmation via imaging and IgE-mediated fungal response testing, a newer and more specialized documentation set than the other indications |
The practical takeaway: if you were denied for one indication, that tells you nothing about how a request for a different indication would go, even for the same patient on the same plan. A prescriber switching a patient's treatment focus — say, from asthma to comorbid CRSwNP — may need to submit an entirely separate authorization with its own documentation, not an amendment to the existing one.
The Newest-Indication Lag: Why "Experimental" Denials Happen
This is the piece that genuinely surprises people, and it's specific to a drug that keeps picking up new FDA approvals the way Dupixent has. COPD with an eosinophilic phenotype was FDA-approved in 2024; chronic spontaneous urticaria, bullous pemphigoid, and allergic fungal rhinosinusitis followed as more recent additions. Each new approval requires every payer, individually, to write and publish an updated clinical policy — and that doesn't happen instantly.
What this looks like in practice: a prescriber submits a fully appropriate, on-label request for one of Dupixent's newer indications, and the plan denies it citing "not FDA-approved" or "experimental/investigational" — not because the plan disputes the science, but because its own clinical policy document hasn't been refreshed to reflect the newer approval yet. The documented fix is to include the FDA approval letter for that specific indication, along with the pivotal trial data supporting it, directly in the appeal, rather than treating the denial as a final answer about coverage.
If you're pursuing one of Dupixent's more recently approved uses, it's worth asking your prescriber's office directly whether they've seen this specific denial pattern with your plan before — for a newer indication, a policy-lag denial is common enough that many specialty pharmacy and prior authorization teams recognize it on sight.
The Concurrent-Biologic Exclusion Most People Don't Know About
Here's a category of denial that has nothing to do with formularies or step therapy in the usual sense, and it's specific to biologics like Dupixent. Several payer clinical policies explicitly state that a member won't be approved for Dupixent while concurrently using certain other biologic therapies that treat an overlapping condition — respiratory biologics like Nucala, Fasenra, or Tezspire being common examples in asthma-related policies.
If you're being denied for this reason, the standard step-therapy argument — "I tried the required conventional therapy first" — doesn't address the actual objection. What the exception request needs to address instead is why concurrent use is clinically necessary, or, more commonly, that the patient is transitioning off the other biologic rather than adding Dupixent on top of it. This is a meaningfully different argument, and conflating it with a standard step-therapy exception is a common reason these specific requests get stuck.
When Step Therapy Means Another Biologic, Not a Cream or Inhaler
Most explanations of "step therapy" assume the required prior treatment is a conventional, non-biologic option — a topical steroid, an inhaler, an antihistamine. That's usually true for Dupixent's initial-request criteria. But Dupixent no longer has the field to itself: newer competitors like Adbry and Ebglyss in atopic dermatitis, and Nucala, Fasenra, Tezspire, and Xolair across various respiratory and allergic conditions, have entered several of the same treatment categories.
On some regional or Medicaid managed care formularies, a plan may now prefer a different biologic within the same class over Dupixent for a specific indication — meaning the "step therapy" you're being asked to satisfy isn't a cream or an inhaler at all, but a documented trial of a competing biologic first. If your prescriber has a specific reason Dupixent is the more appropriate choice for your case — a different mechanism of action, a broader label covering your comorbid conditions, or a documented issue with the preferred alternative — that reasoning needs to be explicit in the request, since a reviewer comparing two biologics side by side is a different clinical conversation than comparing a biologic to a topical cream.
A Real Example: How State Law Can Erase the Need for an Exception
This is worth knowing about even if you don't live in the state it applies to, because it illustrates how much state-level policy can change the picture: as of January 1, 2026, Illinois eliminated step-therapy requirements for certain Dupixent requests under specific marketplace plan types, under a state law change reflected directly in at least one major payer's published clinical policy for the state.
Why this matters beyond Illinois: state step-therapy reform laws are not uniform, and they don't apply the same way to every plan type — ERISA self-funded employer plans, for instance, are typically outside state law's reach entirely. Before assuming you need to satisfy a step-therapy requirement at all, it's worth asking your plan directly whether your specific state and plan type are subject to a step-therapy override law, since the answer genuinely varies and can eliminate the exception process altogether rather than just speeding it up.
What Belongs in the Request
Because the criteria differ so much by indication, a generic medical-necessity letter tends to underperform for Dupixent specifically. What consistently works better is documentation matched to the indication being requested:
- Diagnostic confirmation specific to that indication — lab values, imaging, biopsy results, or specialist evaluation, matching whatever the plan's own published criteria for that condition require.
- Prior therapy history with outcomes, not just a list of drug names — duration tried, why it failed or wasn't tolerated, and any objective measures of continued disease activity.
- For a newer indication, the FDA approval letter and the underlying pivotal trial data, submitted proactively rather than only after a policy-lag denial.
- For a concurrent-biologic situation, a clear statement of whether the request involves switching from or adding to existing biologic therapy, and the specific clinical reasoning either way.
How Long Approvals Last, by Indication
Once approved, Dupixent authorizations aren't uniform in length either — another place where treating "Dupixent coverage" as one single thing leads to confusion.
| Indication | Typical Initial Authorization | Typical Continuation |
|---|---|---|
| Atopic dermatitis | Commonly 6 months | 12 months, with documented clinical response |
| Asthma | Commonly 4–6 months | 12 months |
| CRSwNP | Commonly 6 months | 12 months |
| COPD, chronic spontaneous urticaria, bullous pemphigoid, allergic fungal rhinosinusitis | Varies by plan | Commonly 12 months |
Mark your renewal window a few weeks ahead rather than waiting for a lapse notice — a continuation request needs its own updated documentation of clinical response, not just a request to keep going.
This Isn't the MyWay Copay Card
Worth stating plainly, since the two get conflated: a formulary or step-therapy exception is about getting your plan to approve coverage for Dupixent at all. The DUPIXENT MyWay copay card only reduces what you pay once coverage is already approved, and only if you're commercially insured — it has no bearing on whether a specific indication clears your plan's clinical criteria. If you're uninsured or the coverage question isn't resolved yet, the Dupixent Patient Assistance Program is a separate path worth understanding on its own terms, not a substitute for getting the coverage question sorted first.
If the Request Is Denied
Identify the specific denial reason
"Doesn't meet step-therapy criteria," "experimental/investigational," and "concurrent biologic use" are three different problems that need three different responses — don't assume which one applies without reading the letter closely.
Match your documentation to that specific reason
A policy-lag "experimental" denial needs the FDA approval letter and trial data. A step-therapy denial needs documented prior treatment history. A concurrent-biologic denial needs a clear switching or clinical-necessity rationale.
File a formal appeal within the stated deadline
Include the original denial letter, the updated documentation, and a physician statement addressing the plan's own cited criteria directly.
Ask about expedited review if a treatment gap is a clinical concern
Most plans offer an expedited path when a standard appeal timeline could seriously affect a patient's condition — this generally has to be requested specifically rather than assumed.
Which Situation Applies to You?
What does the denial actually say?
Read the specific stated reason before deciding your next step
Match your indication's checklist
Each of the nine indications has different documentation needs
Submit prior-therapy documentation with outcomes
Not just a list of drug names — durations and results
Is this a newer indication?
Policy-lag denials are common for recent approvals
Submit the FDA approval letter and trial data, or a concurrent-use rationale
These require different evidence than a standard step-therapy appeal
Not sure if step therapy even applies?
Check whether your state and plan type are covered by a step-therapy override law
Common Mistakes
- Assuming a denial for one indication means Dupixent isn't covered on the plan at all, rather than checking the criteria for the specific indication in question.
- Treating an "experimental" denial on a newer indication as final, instead of checking whether it's a policy-lag issue fixable with the FDA approval letter.
- Responding to a concurrent-biologic denial with a standard step-therapy argument, which doesn't address the actual objection.
- Submitting a generic medical-necessity letter instead of documentation matched to the specific indication's published criteria.
- Assuming state step-therapy override protections apply without checking whether your specific plan type — especially a self-funded employer plan — is actually covered by them.
- Confusing a formulary/coverage exception with the MyWay copay card, which solves a completely different problem.
Quick Checklist Before You Submit
| Checklist Item | Status |
|---|---|
| Identified which of the nine indications this request is for | ☐ |
| Pulled your plan's specific published criteria for that indication | ☐ |
| Documented prior therapies with duration and outcome, not just drug names | ☐ |
| If a newer indication, prepared the FDA approval letter and trial data in advance | ☐ |
| Confirmed whether concurrent biologic use is part of the clinical picture | ☐ |
| Checked whether a state step-therapy override law applies to your plan type | ☐ |
| Calendar-flagged your renewal date well before the current authorization expires | ☐ |
Bottom Line
Dupixent is covered on nearly every plan, so a true formulary exception is rarely the real problem — the real complexity is that it treats nine different conditions, each judged against its own separate criteria. Match your documentation to the specific indication and the specific reason on the denial letter, watch for policy-lag "experimental" denials on newer approvals, and don't confuse a concurrent-biologic objection with a standard step-therapy one. If cost, not coverage, ends up being the remaining problem once approval clears, that's a separate conversation covered in our Dupixent savings card guide and Patient Assistance Program guide.